GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report)’s stock price crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $26.28 and traded as low as $23.45. GENMAB A/S/S shares last traded at $23.53, with a volume of 2,007,818 shares traded.
GENMAB A/S/S Trading Down 0.8 %
The business has a fifty day moving average price of $26.28 and a 200-day moving average price of $27.44.
GENMAB A/S/S Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Featured Stories
- Five stocks we like better than GENMAB A/S/S
- Top Biotech Stocks: Exploring Innovation Opportunities
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- What is MarketRank™? How to Use it
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- Do ETFs Pay Dividends? What You Need to Know
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
